112P Women with short survival after diagnosis of metastatic breast cancer: A population-based registry study

Abstract

non-luminal disease with ET had a mPFS of 2.9 and 3.7m (p¼0.99); with target therapies + ET, 13.8 and 1.7m (p¼0.026) and with ET 7.0 and 6.1m (p¼0.094). Pts who showed progression to CDK4/6i as the best response (n¼19) had a mPFS of 1.7m when treated with ET combinations (n¼4) and 8.1m with CT (n¼15).Conclusions: Our exploratory results show limited benefit with post-CDK4/6i therapies, independently from previous PFS. PAM50 subtype remains prognostic in this context. Primary CDK4/6i refractory tumors might benefit more from CT than ET.Legal entity responsible for the study: Hospital Clinic y Provincial of Barcelona.